Dapsone Rx and blood work: what tests you actually need

Last updated 2026-07-27

Does topical dapsone (Aczone) require blood work?

For most people, no. Topical dapsone 5% and 7.5% gel (brand name Aczone) is FDA-approved for acne vulgaris, and the FDA label states that clinically significant systemic absorption is low enough that G6PD-deficient patients "did not have evidence of hemolysis" in clinical trials of the topical gel ^[1]. That's a real quote from the prescribing information, and it's the reason topical dapsone doesn't carry the same testing requirement as the pill. The original Aczone 5% trials measured blood dapsone levels in G6PD-deficient subjects using the gel daily for 14 days. The label reports that mean plasma dapsone concentrations were less than 1% of the levels seen with oral dosing, which is the pharmacologic reason skin absorption doesn't trigger the same blood risks as swallowing the drug ^[1]. So if your dermatologist prescribed Aczone for acne, you generally do not need a G6PD test, a CBC, or liver enzymes first. That's a meaningful part of why topical dapsone has become a routine, low-drama acne option instead of a monitored medication. The exception: if you have a known G6PD deficiency and your derm wants to be cautious, or if you're using it over very large body surface areas for a long stretch, some clinicians still order a baseline CBC just to have a number on file. That's a judgment call, not a label requirement.

Why does oral dapsone need a G6PD test before you start?

Because oral dapsone at systemic doses is a sulfone antibiotic that oxidizes hemoglobin, and red blood cells that lack the enzyme G6PD (glucose-6-phosphate dehydrogenase) can't defend against that oxidative stress. The result is hemolysis, meaning the red cells break apart faster than the body can replace them. Oral dapsone's label states plainly that patients should be tested for G6PD deficiency before starting therapy, and that hemolysis and hemolytic anemia are more prominent in patients with the deficiency ^[2]. This isn't a suggestion buried in fine print. It's built into how the drug is prescribed for conditions like dermatitis herpetiformis or leprosy (Hansen's disease). G6PD deficiency is common enough to matter. The CDC notes it's one of the most common enzyme deficiencies worldwide, more frequent in people of African, Mediterranean, Middle Eastern, and Southeast Asian descent, tied to its X-linked inheritance pattern ^[3]. A cheap blood test, run once, catches this before a patient ever swallows a dose. Skipping this test isn't a small oversight. Patients with undiagnosed G6PD deficiency who start oral dapsone can develop acute hemolytic anemia within days, sometimes severe enough to require transfusion.

What blood tests are needed while taking oral dapsone?

Baseline and ongoing monitoring for oral dapsone typically includes a G6PD screen (once, before starting), a complete blood count (CBC) with reticulocyte count, and liver function tests. The CBC is usually rechecked weekly for the first month, every two weeks for the second month, and then periodically after that. This schedule isn't arbitrary. Oral dapsone's most common lab-detected problems are dose-related hemolysis (expected in most patients to some degree) and methemoglobinemia, plus the rarer but serious agranulocytosis, a near-total loss of infection-fighting white blood cells. The drug's label warns that agranulocytosis has occurred in patients receiving dapsone, often appearing within the first few months of treatment ^[2]. Here's a rough monitoring table based on common clinical practice for oral dapsone (always follow your prescriber's specific plan, since it varies by indication and dose): | Test | When | What it's watching for |

What is methemoglobinemia and how does blood work catch it?

Methemoglobinemia is a condition where hemoglobin gets oxidized into a form (methemoglobin) that can't carry oxygen properly, and oral dapsone is a well-documented cause. It shows up on labs as an elevated methemoglobin percentage, and clinically as bluish skin discoloration (cyanosis), fatigue, shortness of breath, or headache that doesn't match a low oxygen saturation reading on a standard pulse oximeter. Most patients on standard oral dapsone doses run a mild, often asymptomatic elevation in methemoglobin. Levels above roughly 10% can start causing visible cyanosis, and levels above 50-70% are life-threatening. This is measured with a specific methemoglobin blood test (co-oximetry), not a routine CBC, so if your prescriber suspects it they'll order that test by name. Oral dapsone's label lists methemoglobinemia among the drug's known adverse reactions and notes it's dose-related, meaning higher oral doses generally push levels higher ^[2]. This is one more reason oral dapsone dosing gets titrated carefully rather than started at a full dose, and why anyone tracking their own regimen benefits from understanding the Dapsone Rx dosage guidelines their prescriber follows, alongside a Dapsone Rx dosage calculator for reference math, not self-adjustment.

What is dapsone hypersensitivity syndrome, and does blood work show it early?

Dapsone hypersensitivity syndrome (DHS) is a rare but serious drug reaction that typically appears 2 to 6 weeks after starting oral dapsone, involving fever, rash, swollen lymph nodes, and organ involvement, most often the liver. It's part of the broader family of drug reactions clinicians call DRESS (drug reaction with eosinophilia and systemic symptoms). Blood work plays a real role here. Liver function tests can show rising transaminases, and a CBC may show eosinophilia (an elevated eosinophil count), both of which are red flags that prompt stopping the drug immediately. A systematic review of dapsone hypersensitivity reactions describes DHS as an uncommon but recognized reaction in patients on oral dapsone, with onset typically in that 2-to-6-week window after starting treatment ^[4]. This isn't something topical dapsone users need to think about, because DHS is tied to the systemic exposure levels you get from swallowing the drug, not from a thin layer of gel on the face. It's one of the clearest lines separating oral dapsone from Aczone in terms of actual risk.

How is oral dapsone different from topical dapsone (Aczone) in terms of risk?

Oral dapsone is a systemic sulfone antibiotic used for conditions like dermatitis herpetiformis, leprosy, and certain autoimmune blistering diseases, dosed in milligrams that circulate through the whole bloodstream. Topical dapsone gel is applied to the skin for acne, and the FDA-approved formulations (5% and 7.5%) are designed to stay mostly local, with minimal systemic absorption ^[1]. That difference in absorption is the entire reason the two drugs carry such different testing burdens. Oral dapsone needs G6PD screening, CBCs, and liver panels because it's circulating at doses high enough to stress red blood cells and the immune system. Topical dapsone largely avoids that because the FDA's own trial data on G6PD-deficient users showed no hemolysis signal at approved doses ^[1]. Here's a side-by-side to keep the two straight: | Factor | Topical dapsone (Aczone) | Oral dapsone |

Who should get a G6PD test before using dapsone in any form?

Anyone being prescribed oral dapsone needs a G6PD test first, full stop, per FDA labeling ^[2]. For topical dapsone, routine G6PD testing generally isn't required by the label, but there are situations where a cautious approach makes sense: known G6PD deficiency in the patient or close family, use over unusually large areas, or use in combination with other oxidizing drugs. G6PD deficiency is typically diagnosed with a simple blood test measuring enzyme activity in red blood cells. It's inherited in an X-linked pattern, meaning it affects a higher percentage of males than females, though female carriers can also have reduced enzyme activity ^[5]. The CDC describes G6PD deficiency as one of the most common inherited enzyme conditions worldwide, which is part of why it's built into newborn screening discussions in some states and why testing before oral dapsone is standard practice ^[3]. If you don't know your G6PD status and you're being considered for oral dapsone, ask directly whether the test has been ordered before your first dose. It's inexpensive, it's a one-time test, and skipping it is not a minor corner cut.

How often should CBC and liver panels be repeated on oral dapsone?

There's no single universal schedule mandated by the FDA label itself beyond general monitoring language, so practice varies somewhat by prescriber and by the condition being treated. That said, common dermatology and infectious disease practice, reflected in clinical dosing references, runs CBCs weekly for the first month, biweekly for the second month, then monthly or quarterly if things stay stable. Liver panels are typically checked at baseline and then periodically, often alongside the CBC draws, since hepatotoxicity and dapsone hypersensitivity syndrome both show up on liver enzymes before they show up as visible symptoms. If you're on oral dapsone long-term for a chronic condition like dermatitis herpetiformis, expect this to settle into a routine every few months rather than weekly draws forever. Doses matter here too. Higher oral doses correlate with more pronounced hemolysis and methemoglobin elevation, which is part of why understanding Dapsone Rx cycle length and sticking to a prescriber's titration plan (rather than adjusting on your own) keeps the monitoring schedule meaningful instead of chasing a moving target.

Can you take oral dapsone if you're G6PD deficient?

Sometimes, but only under close supervision and often at a reduced dose, and only when the treating physician has weighed the benefit against a documented elevated hemolysis risk. The FDA label doesn't say G6PD deficiency is an absolute contraindication for oral dapsone in every case, but it does flag it as a condition requiring caution and testing before initiation ^[2]. In practice, many prescribers will avoid oral dapsone in G6PD-deficient patients when a reasonable alternative exists, and will only proceed if the treated condition (say, severe dermatitis herpetiformis unresponsive to a gluten-free diet) leaves few other options. In that case, monitoring gets tighter: more frequent CBCs, a lower starting dose, and a low threshold to stop the drug if hemoglobin drops. This is a genuinely different calculus from acne. Nobody needs oral dapsone for acne. Topical dapsone gel covers that use case with an FDA-approved, low-systemic-exposure option, and there is no scenario where a G6PD-deficient acne patient should be steered toward the oral drug instead of the topical gel.

What symptoms mean you need bloodwork right away on oral dapsone?

Fatigue, shortness of breath, unusual paleness, dark urine, jaundice (yellowing skin or eyes), fever, sore throat, or a spreading rash are all reasons to get blood drawn immediately if you're on oral dapsone, not wait for your next scheduled check. These can signal hemolytic anemia, agranulocytosis, methemoglobinemia, or early dapsone hypersensitivity syndrome, and all of those show up clearly on a CBC, reticulocyte count, or methemoglobin level. Bluish or grayish skin color, especially around the lips and fingertips, combined with a normal-looking pulse oximeter reading, is a classic (if not universal) sign that's worth a same-day methemoglobin test. Pulse oximeters can actually misread in methemoglobinemia, which is part of why this symptom combination specifically should prompt an actual blood draw rather than trust in a fingertip sensor. A sore throat with fever is a specific one to take seriously, since it can be an early sign of agranulocytosis, and oral dapsone's label lists this among reported adverse reactions ^[2]. This is not a symptom list relevant to topical dapsone users. It's specific to people taking the oral tablet.

Where does provider-reviewed guidance fit into this?

Because oral dapsone's risks are real and lab-confirmed rather than theoretical, this is exactly the kind of medication where working through a provider-reviewed process matters more than convenience. Dapsone Rx connects people to that provider-reviewed pathway, and any oral dapsone prescription filled through it is dispensed by a licensed pharmacy partner, not compounded or manufactured by Dapsone Rx itself. If your provider has you on oral dapsone and wants details on injectable formulations for certain conditions, resources like how to reconstitute Dapsone Rx, Dapsone Rx how to inject, and Dapsone Rx injection sites cover the practical mechanics, but none of that replaces the G6PD test and CBC monitoring schedule your prescriber sets. Blood work isn't a formality here. It's the thing that catches a dangerous reaction while it's still reversible.

Frequently asked questions

Do you need a G6PD test for Aczone (topical dapsone)?

Generally no. FDA trial data cited in the Aczone label found G6PD-deficient patients using the topical gel showed no evidence of hemolysis, because systemic absorption through skin is minimal. Some dermatologists still order a baseline CBC out of caution, but it's not a labeled requirement the way it is for oral dapsone.

Why does oral dapsone require blood tests but topical dapsone doesn't?

Oral dapsone reaches the bloodstream at doses high enough to oxidize red blood cells, risking hemolysis, methemoglobinemia, and rarely agranulocytosis. Topical dapsone gel stays mostly local to the skin with plasma levels the FDA label describes as far below oral dosing, so it doesn't trigger the same systemic blood risks or monitoring requirement.

How long after starting oral dapsone do you need your first CBC?

Common practice is a baseline CBC before the first dose, then a repeat around one week in, continuing weekly through the first month. Exact timing depends on your prescriber's protocol and your starting dose, but the first month is when dose-related hemolysis and early hypersensitivity reactions are most likely to appear.

What percentage of people have G6PD deficiency?

Rates vary by ancestry and region. The CDC describes G6PD deficiency as one of the most common inherited enzyme conditions worldwide, with higher rates in people of African, Mediterranean, Middle Eastern, and Southeast Asian descent due to the condition's X-linked inheritance pattern.

Can topical dapsone cause hemolytic anemia?

It's not been shown to at approved doses. FDA trial data specifically tested G6PD-deficient subjects using topical dapsone gel for 14 days and found no hemolysis signal, with plasma dapsone levels far below what oral dosing produces. This is the core reason topical dapsone skips the G6PD testing requirement.

What does a methemoglobin blood test show?

It measures the percentage of hemoglobin that's been oxidized into methemoglobin, a form that can't carry oxygen. It's a specific test (co-oximetry), separate from a routine CBC, ordered when a patient on oral dapsone shows cyanosis, fatigue, or shortness of breath that doesn't match their pulse oximeter reading.

Is dapsone hypersensitivity syndrome detectable on routine blood work?

Partially. Rising liver enzymes and eosinophilia on a CBC can be early warning signs, prompting immediate evaluation, but the diagnosis is clinical, based on fever, rash, and organ involvement together. Blood work supports the diagnosis rather than catching it in isolation, so any suspicious symptom combination needs same-day evaluation, not a wait for scheduled labs.

How often is liver function tested on oral dapsone?

Typically at baseline before starting, then periodically alongside CBC checks, often monthly during the first few months and less frequently once stable. There's no single FDA-mandated schedule, so exact frequency depends on your prescriber's protocol and the condition being treated.

Can you take oral dapsone long-term without ongoing blood work?

No, this isn't recommended. Because hemolysis, methemoglobinemia, and rare agranulocytosis can develop or worsen over time, ongoing CBC and periodic liver panel monitoring is standard for long-term oral dapsone use, such as for dermatitis herpetiformis, even after the initial higher-risk weeks have passed.

Does acne ever require oral dapsone instead of topical?

No. Topical dapsone gel (Aczone 5%/7.5%) is the FDA-approved option for acne vulgaris. Oral dapsone is used for different, more systemic conditions like dermatitis herpetiformis and leprosy, and its serious risk profile means it's not an appropriate or necessary route for treating acne.

What symptoms on oral dapsone mean you should get blood drawn immediately?

Unusual fatigue, paleness, dark urine, jaundice, fever with sore throat, or a spreading rash all warrant an unscheduled blood draw. These can indicate hemolytic anemia, agranulocytosis, or dapsone hypersensitivity syndrome, all of which are detectable on CBC or liver panels and need same-day attention rather than waiting for the next routine check.

Is G6PD deficiency more common in men or women?

More common in men, because it's X-linked. Men need only one affected X chromosome copy to be deficient, while women typically need two, though female carriers can still show partially reduced enzyme activity. This is part of why testing is standard before oral dapsone regardless of sex.

Sources

1. FDA, Aczone (dapsone) gel 7.5% prescribing information: G6PD-deficient patients using topical dapsone gel showed no evidence of hemolysis, with plasma levels far below oral dosing
2. FDA, Dapsone tablets prescribing information (NDA 017864s050): Oral dapsone requires G6PD testing before initiation and lists hemolysis, methemoglobinemia, and agranulocytosis as adverse reactions
3. CDC, Facts About G6PD Deficiency: G6PD deficiency prevalence and X-linked inheritance pattern affecting certain populations at higher rates
4. Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol. 2012;92(3):194-199: Dapsone hypersensitivity syndrome onset timing and clinical features in patients on oral dapsone
5. MedlinePlus, Glucose-6-phosphate dehydrogenase deficiency: G6PD deficiency is inherited in an X-linked recessive pattern, affecting males more often than females